Table 1. Characteristics of the 10... | American Society of Hematology

Table 1.

Characteristics of the 10 Allogeneic BMT Donor/Recipient Pairs Recruited for This Study, Including Gender of Recipient and Donor, Recipient's Class I MHC Typing, Recipient's Diagnosis, Source of Donor Hematopoietic Stem Cells, Regimen Used for GVHD Prophylaxis, and Acute GVHD Status of the Recipient

Pair No.	Recipient	Donor	HLA-A	HLA-C	HLA-B	Diagnosis	Source of Donor Stem Cells	GVHD Prophylaxis	Acute GVHD, Grade
1	Male	Female	2, 11	w6, w3	37, 62	ALL	BM	ATG/MTX/CsA	III
2	Female	Male	11, 24	w3	51, 44	AML	BM	MTX/CsA	II
3	Male	Male	1, 32	w7, w1	8, 27	MDS/AML	BM	MTX/CsA	III
4	Male	Female	29, 30	w7, w6	8, 13	MDS/AML	G-PBSC	MTX/CsA	I
5	Male	Male	3	w7	7	MM	G-PBSC	MTX/CsA	III
6	Male	Male	2, 3	w5, w7	44, 35	ALL	G-PBSC	MTX/CsA	II
7	Male	Male	23, 2	w7	58, 7	ALL	BM	ATG/MTX/CsA	III
8	Female	Male	3, 30	w3, w4	70, 53	MDS/AML	G-PBSC	MTX/CsA	I
9	Female	Female	3, 24	w2	51, 38	AML	G-PBSC	MTX/CsA	I
10	Male	Female	2, 3	w4, w7	35, 7	AML	G-PBSC	MTX/CsA	II

Pair No.	Recipient	Donor	HLA-A	HLA-C	HLA-B	Diagnosis	Source of Donor Stem Cells	GVHD Prophylaxis	Acute GVHD, Grade
1	Male	Female	2, 11	w6, w3	37, 62	ALL	BM	ATG/MTX/CsA	III
2	Female	Male	11, 24	w3	51, 44	AML	BM	MTX/CsA	II
3	Male	Male	1, 32	w7, w1	8, 27	MDS/AML	BM	MTX/CsA	III
4	Male	Female	29, 30	w7, w6	8, 13	MDS/AML	G-PBSC	MTX/CsA	I
5	Male	Male	3	w7	7	MM	G-PBSC	MTX/CsA	III
6	Male	Male	2, 3	w5, w7	44, 35	ALL	G-PBSC	MTX/CsA	II
7	Male	Male	23, 2	w7	58, 7	ALL	BM	ATG/MTX/CsA	III
8	Female	Male	3, 30	w3, w4	70, 53	MDS/AML	G-PBSC	MTX/CsA	I
9	Female	Female	3, 24	w2	51, 38	AML	G-PBSC	MTX/CsA	I
10	Male	Female	2, 3	w4, w7	35, 7	AML	G-PBSC	MTX/CsA	II

Abbreviations: MDS/AML, AML arising in the setting of an antecedent myelodysplastic syndrome; MM, multiple myeloma; G-PBSC, granulocyte colony-stimulating factor–mobilized PBSC; ATG, antithymocyte globulin; MTX, methotrexate; CsA, cyclosporine A.

View Large

This Feature Is Available To Subscribers Only